Canlyniadau Chwilio - Jordi Remón

Mireinio'r Canlyniadau
  1. 1
    Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment

    Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment gan Jordi Remón, Benjamin Besse

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Precision oncology: separating the wheat from the chaff

    Precision oncology: separating the wheat from the chaff gan Jordi Remón, Rodrigo Dienstmann

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

    Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? gan Jordi Remón, Benjamin Besse, Jean‐Charles Soria

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

    Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy gan José Carlos Benítez, Jordi Remón, Benjamin Besse

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

    Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy gan Jordi Remón, Jean‐Charles Soria, Solange Peters

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

    Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients gan Jordi Remón, Conor Steuer, Suresh S. Ramalingam, Enriqueta Felip

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

    EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins gan Jordi Remón, Lizza Hendriks, Andrés F. Cardona, Benjamin Besse

    Cyhoeddwyd 2020
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients

    Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients gan Jordi Remón, Laura Mezquita, J. Corral, Noelia Vilariño, Noemı́ Reguart

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

    Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? gan Jordi Remón, Lizza Hendriks, C. Cabrera, Noemı́ Reguart, Benjamin Besse

    Cyhoeddwyd 2018
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Are liquid biopsies a surrogate for tissue EGFR testing?

    Are liquid biopsies a surrogate for tissue EGFR testing? gan Jonathan W. Goldman, Zorawar S. Noor, Jordi Remón, Benjamin Besse, Nitzan Rosenfeld

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Acute drop in blood monocyte count differentiates NEC from other causes of feeding intolerance

    Acute drop in blood monocyte count differentiates NEC from other causes of feeding intolerance gan Jordi Remón, Richard Kampanatkosol, Rupert Kaul, Jonathan Muraskas, Robert D. Christensen, Akhil Maheshwari

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Small cell lung cancer: a slightly less orphan disease after immunotherapy

    Small cell lung cancer: a slightly less orphan disease after immunotherapy gan Jordi Remón, Mihaela Aldea, Benjamin Besse, David Planchard, Martin Reck, Giuseppe Giaccone, Jean‐Charles Soria

    Cyhoeddwyd 2021
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients

    Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients gan Christopher Alvarez‐Breckenridge, Jordi Remón, Yolanda Piña, Edwin Nieblas‐Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K. Brastianos

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges

    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges gan Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, Pawan Kumar Singh, Jessica Menis, Giannis Mountzios, Lizza Hendriks

    Cyhoeddwyd 2023
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    MET alterations in NSCLC—Current Perspectives and Future Challenges

    MET alterations in NSCLC—Current Perspectives and Future Challenges gan Jordi Remón, Lizza Hendriks, Giannis Mountzios, Rosario García‐Campelo, Stephanie P.L. Saw, Dipesh Uprety, Gonzalo Recondo, Guillermo Villacampa, Martin Reck

    Cyhoeddwyd 2022
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

    Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer gan Arianna Marinello, Marco Tagliamento, Arianna Pagliaro, Nicole Conci, Eugenia Cella, Damien Vasseur, Jordi Remón, Antonin Lévy, Filippo Gustavo Dall’Olio, Benjamin Besse

    Cyhoeddwyd 2024
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613

    The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613 gan Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eléonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse, Rafał Dziadziuszko

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018

    Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 gan Jordi Remón, Myung‐Ju Ahn, Nicolas Girard, Melissa L. Johnson, Dong‐Wan Kim, Gilberto Lopes, Rathi N. Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

    Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer gan Idoko Salifu, Navneet Singh, Maria Berraondo, Jordi Remón, Stephanie Salifu, Eric A. Severson, Ángela Quintana, Sandra Peiró, Shakti Ramkissoon, Laura Vidal, Isagani Chico, Kamal S. Saini

    Cyhoeddwyd 2023
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i>- and <i>ALK</i>-Rearranged Lung Cancers

    Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i>- and <i>ALK</i>-Rearranged Lung Cancers gan Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remón, Jean–Yves Scoazec, Fabrice André, Jean‐Charles Soria, Luc Friboulet

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: